Medical - Devices
Compare Stocks
4 / 10Stock Comparison
APYX vs AEYE vs ALKT vs SSKN
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Application
Software - Application
Medical - Devices
APYX vs AEYE vs ALKT vs SSKN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Software - Application | Software - Application | Medical - Devices |
| Market Cap | $149M | $100M | $1.87B | $7M |
| Revenue (TTM) | $56M | $40M | $472M | $31M |
| Net Income (TTM) | $-9M | $-3M | $-50M | $-11M |
| Gross Margin | 38.1% | 78.3% | 57.4% | 57.8% |
| Operating Margin | -7.7% | -7.9% | -9.3% | -33.3% |
| Forward P/E | — | — | 21.7x | — |
| Total Debt | $39M | $721K | $354M | $16M |
| Cash & Equiv. | $32M | $5M | $63M | $7M |
APYX vs AEYE vs ALKT vs SSKN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Apyx Medical Corpor… (APYX) | 100 | 35.1 | -64.9% |
| AudioEye, Inc. (AEYE) | 100 | 32.0 | -68.0% |
| Alkami Technology, … (ALKT) | 100 | 36.5 | -63.5% |
| STRATA Skin Science… (SSKN) | 100 | 1.1 | -98.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APYX vs AEYE vs ALKT vs SSKN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
APYX is the #2 pick in this set and the best alternative if momentum is your priority.
- +184.8% vs SSKN's -93.3%
AEYE is the clearest fit if your priority is long-term compounding.
- 102.2% 10Y total return vs ALKT's -59.5%
- -7.6% margin vs SSKN's -35.6%
ALKT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.30
- Rev growth 32.9%, EPS growth -12.2%, 3Y rev CAGR 29.5%
- Lower volatility, beta 1.30, Low D/E 97.7%, current ratio 2.09x
- Beta 1.30, current ratio 2.09x
SSKN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs SSKN's 0.6% | |
| Quality / Margins | -7.6% margin vs SSKN's -35.6% | |
| Stability / Safety | Beta 1.30 vs AEYE's 2.29 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +184.8% vs SSKN's -93.3% | |
| Efficiency (ROA) | -5.9% ROA vs SSKN's -35.9%, ROIC -8.6% vs -38.9% |
APYX vs AEYE vs ALKT vs SSKN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
APYX vs AEYE vs ALKT vs SSKN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
APYX leads in 1 of 6 categories
SSKN leads 1 • ALKT leads 1 • AEYE leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
APYX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKT is the larger business by revenue, generating $472M annually — 15.2x SSKN's $31M. AEYE is the more profitable business, keeping -7.6% of every revenue dollar as net income compared to SSKN's -35.6%. On growth, APYX holds the edge at +31.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $56M | $40M | $472M | $31M |
| EBITDAEarnings before interest/tax | -$4M | -$504,000 | -$12M | -$5M |
| Net IncomeAfter-tax profit | -$9M | -$3M | -$50M | -$11M |
| Free Cash FlowCash after capex | -$9M | $2M | $44M | -$4M |
| Gross MarginGross profit ÷ Revenue | +38.1% | +78.3% | +57.4% | +57.8% |
| Operating MarginEBIT ÷ Revenue | -7.7% | -7.9% | -9.3% | -33.3% |
| Net MarginNet income ÷ Revenue | -16.4% | -7.6% | -10.6% | -35.6% |
| FCF MarginFCF ÷ Revenue | -16.1% | +5.5% | +9.4% | -11.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +31.7% | +7.9% | +28.9% | -21.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +58.3% | +29.0% | -22.7% | -5.9% |
Valuation Metrics
SSKN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $149M | $100M | $1.9B | $7M |
| Enterprise ValueMkt cap + debt − cash | $157M | $96M | $2.2B | $16M |
| Trailing P/EPrice ÷ TTM EPS | -13.19x | -32.36x | -37.89x | -0.67x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 21.69x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.82x | 2.49x | 4.20x | 0.20x |
| Price / BookPrice ÷ Book value/share | 10.12x | 20.91x | 5.00x | 1.34x |
| Price / FCFMarket cap ÷ FCF | — | — | 45.09x | — |
Profitability & Efficiency
Evenly matched — AEYE and ALKT each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
ALKT delivers a -14.0% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-8 for SSKN. AEYE carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to SSKN's 3.31x. On the Piotroski fundamental quality scale (0–9), APYX scores 4/9 vs ALKT's 3/9, reflecting mixed financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -88.5% | -47.8% | -14.0% | -8.4% |
| ROA (TTM)Return on assets | -14.9% | -9.5% | -5.9% | -35.9% |
| ROICReturn on invested capital | -22.1% | -42.4% | -8.6% | -38.9% |
| ROCEReturn on capital employed | -11.8% | -17.7% | -9.3% | -36.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 3 | 4 |
| Debt / EquityFinancial leverage | 2.65x | 0.15x | 0.98x | 3.31x |
| Net DebtTotal debt minus cash | $8M | -$5M | $290M | $9M |
| Cash & Equiv.Liquid assets | $32M | $5M | $63M | $7M |
| Total DebtShort + long-term debt | $39M | $721,000 | $354M | $16M |
| Interest CoverageEBIT ÷ Interest expense | -0.97x | -2.79x | -3.73x | -4.63x |
Total Returns (Dividends Reinvested)
ALKT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKT five years ago would be worth $4,510 today (with dividends reinvested), compared to $109 for SSKN. Over the past 12 months, APYX leads with a +184.8% total return vs SSKN's -93.3%. The 3-year compound annual growth rate (CAGR) favors ALKT at 12.2% vs SSKN's -74.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.7% | -18.7% | -23.1% | -86.2% |
| 1-Year ReturnPast 12 months | +184.8% | -27.9% | -37.8% | -93.3% |
| 3-Year ReturnCumulative with dividends | +2.3% | +20.6% | +41.1% | -98.3% |
| 5-Year ReturnCumulative with dividends | -62.9% | -60.2% | -54.9% | -98.9% |
| 10-Year ReturnCumulative with dividends | -45.0% | +102.2% | -59.5% | -99.6% |
| CAGR (3Y)Annualised 3-year return | +0.8% | +6.4% | +12.2% | -74.5% |
Risk & Volatility
Evenly matched — APYX and SSKN each lead in 1 of 2 comparable metrics.
Risk & Volatility
SSKN is the less volatile stock with a -0.24 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APYX currently trades 79.1% from its 52-week high vs SSKN's 4.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.96x | 2.29x | 1.30x | -0.24x |
| 52-Week HighHighest price in past year | $4.50 | $16.39 | $31.66 | $3.86 |
| 52-Week LowLowest price in past year | $1.08 | $5.31 | $14.11 | $0.11 |
| % of 52W HighCurrent price vs 52-week peak | +79.1% | +49.4% | +55.1% | +4.5% |
| RSI (14)Momentum oscillator 0–100 | 28.6 | 61.3 | 50.9 | 41.6 |
| Avg Volume (50D)Average daily shares traded | 162K | 194K | 1.9M | 14K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: APYX as "Buy", ALKT as "Buy". Consensus price targets imply 68.5% upside for APYX (target: $6) vs 26.2% for ALKT (target: $22).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | — |
| Price TargetConsensus 12-month target | $6.00 | — | $22.00 | — |
| # AnalystsCovering analysts | 9 | — | 12 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
APYX leads in 1 of 6 categories (Income & Cash Flow). SSKN leads in 1 (Valuation Metrics). 2 tied.
APYX vs AEYE vs ALKT vs SSKN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is APYX or AEYE or ALKT or SSKN a better buy right now?
For growth investors, Alkami Technology, Inc.
(ALKT) is the stronger pick with 32. 9% revenue growth year-over-year, versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). Analysts rate Apyx Medical Corporation (APYX) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — APYX or AEYE or ALKT or SSKN?
Over the past 5 years, Alkami Technology, Inc.
(ALKT) delivered a total return of -54. 9%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — APYX or AEYE or ALKT or SSKN?
By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.
(SSKN) is the lower-risk stock at -0. 24β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately -1038% more volatile than SSKN relative to the S&P 500. On balance sheet safety, AudioEye, Inc. (AEYE) carries a lower debt/equity ratio of 15% versus 3% for STRATA Skin Sciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — APYX or AEYE or ALKT or SSKN?
By revenue growth (latest reported year), Alkami Technology, Inc.
(ALKT) is pulling ahead at 32. 9% versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). On earnings-per-share growth, the picture is similar: Apyx Medical Corporation grew EPS 59. 1% year-over-year, compared to -12. 2% for Alkami Technology, Inc.. Over a 3-year CAGR, ALKT leads at 29. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — APYX or AEYE or ALKT or SSKN?
AudioEye, Inc.
(AEYE) is the more profitable company, earning -7. 6% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is APYX or AEYE or ALKT or SSKN more undervalued right now?
Analyst consensus price targets imply the most upside for APYX: 68.
5% to $6. 00.
07Which pays a better dividend — APYX or AEYE or ALKT or SSKN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is APYX or AEYE or ALKT or SSKN better for a retirement portfolio?
For long-horizon retirement investors, STRATA Skin Sciences, Inc.
(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). Apyx Medical Corporation (APYX) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, APYX: -45. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between APYX and AEYE and ALKT and SSKN?
These companies operate in different sectors (APYX (Healthcare) and AEYE (Technology) and ALKT (Technology) and SSKN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: APYX is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; SSKN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.